Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STRO-006 |
| Synonyms | |
| Therapy Description |
STRO-006 is an antibody-drug conjugate (ADC) comprising an antibody that targets integrin beta-6 (ITGb6) linked to a topoisomerase inhibitor, which may inhibit tumor cell growth (Cancer Res (2026) 86 (7_Supplement): 1713). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STRO-006 | STRO 006|STRO006 | STRO-006 is an antibody-drug conjugate (ADC) comprising an antibody that targets integrin beta-6 (ITGb6) linked to a topoisomerase inhibitor, which may inhibit tumor cell growth (Cancer Res (2026) 86 (7_Supplement): 1713). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07807345 | Phase I | Pembrolizumab + STRO-006 STRO-006 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Not yet recruiting | USA | 0 |